Navigation Links
Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
Date:7/31/2008

SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present information on platinum resistance at the Fourth Annual Moores UCSD Cancer Center Translational Oncology Symposium on Friday, August 1, in San Diego.

Neela Patel, Ph.D., director of preclinical and translational medicine for Poniard Pharmaceuticals, will present on the topic of "Molecular Mechanisms of Platinum Resistance" at 2:30 p.m. Pacific Time. Jerry McMahon, Ph.D., chairman and chief executive officer, will participate in the symposia's concluding panel discussion at 3:15 p.m. Pacific Time.

"Each year, 300,000 cancer patients in the United States are treated with a platinum-based chemotherapy, and most relapse after initial treatment," said Dr. McMahon. "Therefore, intrinsic or acquired resistance to platinums is a significant treatment issue. Picoplatin, our lead product candidate, was designed to overcome platinum resistance, and we are exploring the use of genetic markers of platinum resistance to optimize patient treatment."

About The Rebecca and John Moores UCSD Cancer Center

The Rebecca and John Moores UCSD Cancer Center seeks to bring the finest minds in treatment and research under one roof to share the latest advances in the oncology field, and to create a fertile atmosphere that promotes networking and collaboration opportunities of benefit to all participants.

Information about the Moores UCSD Cancer Center and the Translational Oncology Symposium can be found at http://cancer.ucsd.edu/symposium/index.asp.

Abou
'/>"/>

SOURCE Poniard Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, 2015 ... that Roger Jeffs , Ph.D., President and Co-Chief Executive ... on the company,s business at the Deutsche Bank 40 th ... . The presentation will take place on ... can be accessed via a live webcast on the United ...
(Date:4/30/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, announced plans to ... 2015 on May 7, 2015 after the close of ... host a conference call at 4:30 p.m. Eastern Time ... financial results. During the conference call, material information concerning ...
(Date:4/30/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) reported total ... were $4.4 million, compared to $8.0 million during the same ... quarter was $8.9 million, or $0.23 per basic and diluted ... same period in 2014, of $8.7 million, or $0.27 per ... cash, cash equivalents and investments totaled $117.5 million. , ...
(Date:4/30/2015)... April 30, 2015 Nitto Avecia, ... announces its increased capacity and production capability to ... client variety and service fulfillment continues to drive ... improve process throughput capacities. , In ... installed downstream process equipment at its Milford, MA ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... Intercell AG (VSE: ICLL) today announced that it ... U.S. Food and Drug Administration,s (FDA) approval of IXIARO(R), ... (JE). The initial target for use of Intercell,s vaccine ... U.S. market - will be adult travelers and military ...
... DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or ... financial results for 2008. DOR,s revenues for 2008 were ... The increase was due primarily to progress with ... of certain research and development milestones with our subcontractors. ...
... Va., March 31 - Innocoll, Inc. announced that its ... application for its CollaRx(TM) Lidocaine Sponge for the management ... year 13 million patients worldwide suffer from chronic wounds ... 35 percent of all chronic wounds do not ...
Cached Biology Technology:Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 2Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 5Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge 2
(Date:4/1/2015)... 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces the second ... is underway to early access pre-order customers. ... at retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, ... was accepted at all outlets and very easy to ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... Institute and MIT have engineered yeast that can improve ... component to making biofuels a significant part of the ... additive to improve gasoline combustibility, ethanol is often touted ... crisis. But there are significant obstacles to producing ethanol. ...
... manipulate the brain's perception of jaw movement while words ... importance of non-auditory sensory cues in the brain's control ... and David Ostry of McGill University and appear in ... published by Cell Press. , When we speak, ...
... Institute have identified a novel biomarker for brain tumors ... play when the tumor spreads or comes back after ... cerebrospinal fluid of patients with malignant astrocytoma and mediates ... of Clinical Cancer Research. , The biomarker, ...
Cached Biology News:Engineered yeast speeds ethanol production 2Sensory feedback during speech: The brain attunes to more than just sound 2Newly identified biomarker detects and regulates spread of brain tumors 2
... The new MALDI O-TOF creates a ... on an orthogonal platform that has been ... the University of Manitoba. , As the ... orthogonal design and collisional cooling, the prOTOF ...
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
37-1A9...
Biology Products: